• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600664.SS
Share

Harbin Pharmaceutical Group Co., Ltd. Stocks

CN¥ 4.02Last Updated 14.07.2026

Issuer Rating

5/7
Performance

Average

Risk

Low

Recommendation

Hold

Market Cap

CN¥ 1.25B

CN¥ 4.02
Key Takeaways

Risk factor

Low price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Harbin Pharmaceutical Group Co., Ltd. functions as a leading pharmaceutical company, overseeing the complete process from drug discovery and development to manufacturing and global sales. The firm's activities span both domestic Chinese markets and international territories. Its business structure is segmented into seven key areas: Antibiotics, Small-Molecule Drug Formulations, Over-the-Counter (OTC) and Health Products, Modern Chinese Medicine, Biopharmaceutical products, Animal Vaccines, and Pharmaceutical Distribution services. The company's broad product portfolio features a comprehensive selection of penicillin and cephalosporin antibiotics, in addition to vital pharmaceutical intermediates. Its notable offerings include various types of injections, such as Shuang Huanglian and Danshen freeze-dried injections, alongside a wide array of oral medications like roxithromycin dispersible tablets, amoxicillin capsules, and specialized pediatric granules containing paracetamol. The product line also encompasses a diverse range of antibiotics, highlighted by multiple cephalosporin-based injections (e.g., ceftriaxone sodium, cefepime hydrochloride) and penicillin derivatives, alongside extracts from traditional Chinese medicine like Panax ginseng. Furthermore, the group manufactures essential medical protective gear, including disposable surgical and protective masks, as well as isolation and protective gowns. These products are distributed under numerous well-known brands, including Hongyan Yaopin, Guangwei, Renmin Tongtai, and Hayao, among others. The company's headquarters are located in Harbin, China.

Company Valuation

Undervalued
6/7

Considering past and projected metrics, the stock is 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, 'cheap' on EV/EBITDA, undervalued on

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 08:30

Disney's decision to abandon streaming will boost its stock by 40% — Wells Fargo

14.07.2026 07:30

Jefferies recommended buying shares of Hoka's parent company. The brand could replicate UGG's success.

14.07.2026 02:42

Prosecutors from 12 U.S. states have filed a lawsuit against the Paramount-Warner Bros. Discovery deal

14.07.2026 01:22

SK Hynix Led the Decline Among Chipmakers; Oil Prices Suffered Their Sharpest One-Day Drop Since 2020

14.07.2026 00:44

Oil prices jumped by nearly 10%. The price of Brent crude exceeded $83 per barrel

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026